Amber Bio, a trailblazing biotechnology company, has launched with an oversubscribed $26 million seed financing round to pioneer multi-kilobase gene editing platforms. This innovative approach aims to target previously undruggable diseases. The investment round was co-led by early-stage venture capital firm Playground Global and Andreessen Horowitz Bio + Health, with participation from industry leaders such […]
Eli Lilly and Company has unveiled the results of two Phase 3 tirzepatide studies (SURMOUNT-3 and SURMOUNT-4) targeting adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes. Both studies successfully met all primary and key secondary objectives, showcasing the effectiveness of tirzepatide over a placebo. The results saw participants on tirzepatide, after […]
Eli Lilly and Company (Lilly) revealed complete results from its Phase 3 TRAILBLAZER-ALZ 2 study at the 2023 Alzheimer’s Association International Conference (AAIC), indicating that the experimental drug, donanemab, significantly slowed the cognitive and functional decline in patients with early symptomatic Alzheimer’s disease. The data was simultaneously published in the Journal of the American Medical […]
American pharma giant Eli Lilly and Company (Lilly) and Versanis Bio have announced a definitive agreement in which the former will acquire the privately-held clinical-stage biopharmaceutical company. Founded by Aditum Bio in 2021, Versanis Bio is focused on the development of new treatments for cardiometabolic diseases. The acquisition will see Versanis Bio’s leading asset, bimagrumab, […]
RemeGen, a commercial-stage Chinese biotechnology firm, and Innovent Biologics have announced their collaboration in a clinical research and supply agreement. This partnership focuses on conducting clinical trials that explore combination therapies involving novel antibody-drug conjugates (ADCs), specifically, RC88 and RC108, and the PD-1 inhibitor sintilimab injection, TYVYT. As per the agreement, Innovent Biologics will supply […]
Eli Lilly’s oncology arm, Loxo@Lilly, disclosed that The New England Journal of Medicine (NEJM) has published an extensive analysis of results from the BRUIN Phase 1/2 trials on pirtobrutinib, a reversible Bruton’s tyrosine kinase (BTK) inhibitor. Pirtobrutinib is being investigated for use in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who […]
Pharmaceutical giant Eli Lilly and Company (Lilly) has announced its definitive agreement to acquire Nasdaq-listed biopharma innovator Sigilon Therapeutics, in a move set to significantly impact the biopharmaceutical industry and the treatment of chronic diseases. The deal, valued at approximately $309.6 million excluding shares held by Lilly, not only promises to reshape the landscape of […]
Eli Lilly and Company (Lilly) said that tirzepatide has shown superior efficacy over placebo in chronic weight management, according to the results from the phase 3 clinical trial SURMOUNT-2. Tested on patients with obesity or overweight and type 2 diabetes, the trial reported that tirzepatide, at doses of 10 mg and 15 mg, led to […]
Eli Lilly and Company (Lilly) has agreed to acquire US-based biopharmaceutical company DICE Therapeutics, listed on the Nasdaq, in an all-cash deal worth $2.4 billion. DICE Therapeutics has developed the DELSCAPE technology platform for developing novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to address chronic diseases in immunology. Patrik Jonsson […]
Lupin, an Indian pharmaceutical company, has announced a strategic collaboration with Enzene Biosciences, a subsidiary of Alkem Laboratories, to introduce Cetuximab in India. Cetuximab is the first biosimilar developed for Eli Lilly and Company’s Cetuximab, a monoclonal antibody medication used in the treatment of various types of cancer, including head and neck cancer and metastatic […]